Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01237678 (CLINICAL TRIAL / IMGN-901 / LORVOTUZUMAB MERTANSINE / BB-10901)

Study Title
A Study to Test Safety and Efficacy of IMGN901 in Combination With Carboplatin/Etoposide in Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer (NCT01237678)

Trial Description

The purpose of this study is to test safety and efficacy of this combination treatment of IMGN901 (also known as lorvotuzumab mertansine or BB-10901) carboplatin and etoposide in patients with solid tumors and extensive stage small cell lung cancer.

This trial is sponsored by ImmunoGen, Inc. [1]

Study Data

  • Condition: Small Lung Cell Cancer
  • Interventions:
    • Drugs used in this trial
      • IMGN901 (Lorvotuzumab mertansine; BB-10901)
      • Carboplatin
      • Etoposide (Toposar®; Pfitzer, Inc.)
  • Phase: I
  • Estimated Enrollment: 145
  • Start: November 2010
  • Estimated Completion: July 2015

Study Schematic 

(Coming soon)

Click here to Return to Drug map


Last Editorial review: July 10, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar